Work

Autoimmune Hemolytic Anemia From Tofacitinib Use in a Patient With Ulcerative Colitis

Year: 2024

Type: article

Abstract: Tofacitinib is a Janus kinase inhibitor commonly used in the management of rheumatoid arthritis and moderate-to-severe ulcerative colitis. Anemia is a rare side effect of this medication often with minimal changes in hemoglobin levels. We report the first case of autoimmune hemolytic anemia from tofacitinib use in a patient with inflammatory bowel disease. This patient developed transfusion-dependent anemia after the initiation of tofacitinib and underwent extensive workup that revealed a diagnosis of autoimmune hemolytic anemia. The medication was discontinued, and she was treated with steroids and rituximab, leading to the improvement and stabilization of her hemoglobin levels.

Source: ACG Case Reports Journal

DOI: 10.14309/crj.0000000000001528

Authors: Erin Zisman, Rukaiya Bashir-Hamidu, Lauren George

Institutions: University of Maryland, Baltimore, University of Maryland Medical System

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4402924030

FWCI: 0.481

Cites: 14

Cited by: 2

Related to: 10